Hepatitis Treatments and Vaccines: World Market 2012-2022

4.5.8 France: Revenues 2012-2022

There are around 500,000 people suffering from hepatitis B and hepatitis C in France at present. However, in 2009 it was reported that only 90,000 were undergoing long-term treatment for these indications. France is therefore the smallest of the five major European markets, in terms of hepatitis treatment, visiongain estimates. In 2011, revenues for hepatitis treatment and vaccination totalled $0.25bn, accounting for 13.3% of the European and 3.2% of the global market. Hepatitis is not as great a concern for the French population as in other regions of Europe. The low prevalence is in part a result of government initiatives to monitor and reduce hepatitis in the country, which have been in place since 1999. The Institut de Veille Sanitaire launched its third national plan for defeating hepatitis in 2009.

During the forecast period, these government initiatives will help further reduce the cost burden of hepatitis in the French market. The launch of new oral antivirals for hepatitis C will act as a market driver, although with less impact than in other European markets. Between 2011 and 2022, the French hepatitis market will grow from $0.25bn to $0.60bn. Growth will be fastest in the first half of the forecast period, when the market will grow with a CAGR of 11.5% (Table 4.11 and Figure 4.13).

Figure 4.13 French Hepatitis Treatments and Vaccines: Submarket Forecast, 20112022
0.65 0.60 0.55 Market Size ($bn) 0.50 0.45 0.40 0.35 0.30 0.25 0.20

Year

Source: visiongain 2012

www.visiongain.com

Page 74

http://www.bioportfolio.net/report/13641-hepatitis-treatments-andvaccines-world-market.html

Hepatitis Treatments and Vaccines: World Market 2012-2022

Table 4.11 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
2011 France ($bn) Annual Growth (%) CAGR (%) 2017 France ($bn) Annual Growth (%) CAGR (%) 0.46 7 2018 0.49 5 2019 0.52 6 2020 0.55 6 2021 0.57 5 0.25 2012 0.28 10 2013 0.31 11 2014 0.35 12 2015 0.39 13 2016 0.43 11 11.5 2022 0.60 4 5.5

Source: visiongain 2012

4.6 Hepatitis in Asia

As is discussed elsewhere in this report, the prevalence of hepatitis is highest in the Asian region. China alone accounts for more than a quarter of all cases of hepatitis B and C. However, the leading markets in this region have a much smaller share of the global hepatitis market than Western markets such as the US and EU. China, however, is the leading market in terms of revenues, in Asia and also is the second largest national market globally. In emerging markets in the region, the incidence and prevalence of hepatitis C is linked to the lack of available sterile injection equipment, while among the leading causes of hepatitis B is perinatal transfer - infected and untreated mothers passing the infection on to their children.

Over the coming decade, pharmaceutical companies will place more emphasis on bringing drugs to the Asian markets where they are needed most. High treatment costs and a lack of awareness currently mean that many patients are not treated, increasing the mortality rate in the region. Companies targeting Asia will need to price their drugs appropriately, as well as promoting their products well - one cause of the stigma associated with hepatitis in Asia is poor media perception of the virus. With increasing wealth and urbanisation of the populations of emerging Asian markets, greater numbers of patients will be identified and treated, leading to expanding drug markets, visiongain believes.

4.7 China 4.7.1 Increased Vaccination

Reports suggest that vaccination against hepatitis was not common in China until the beginning of the past decade. In September 2002, the Chinese government joined up with The Vaccine Fund to

www.visiongain.com

Page 75

http://www.bioportfolio.net/report/13641-hepatitis-treatments-and-vaccines-world-market.html